


GLOBAL
AMR R&D
HUB



WORLD
HEALTH
SUMMIT

Global AMR R&D Hub Dynamic Dashboard to support evidence-based decision making


Elmar Nimmesgern
Secretariat Lead

PD02 - Developing Antibiotics for
Children to Achieve SDG 3

25.10.20

Global AMR R&D Hub – Dynamic Dashboard

- Collaboration Hub to address challenges and improve coordination in global AMR R&D using a One Health approach
- Twenty members and four observers
- Launched in May 2018 during the 71st WHA
- Dynamic Dashboard started March 2020
- Three galleries presenting investments, the antibacterials clinical pipeline and incentives for antibacterial R&D



The screenshot shows the Global AMR R&D Hub Dynamic Dashboard website. The header includes the logo and navigation links: Search, Contact, Definitions, Library, and Sign in. The main content area features three key metrics: 151 Funders, 7781 Projects, and 6.0bn USD Investment. Below these are three galleries: 'Investments in AMR R&D', 'Antibacterials in clinical development', and 'Incentives for Antibacterial R&D'. Each gallery has a brief description and an 'Enter' button. A survey link is provided at the bottom: 'Please participate in our survey on the Dynamic Dashboard: [Link](#)'. The footer contains copyright information (© 2020, Global AMR R&D Hub), a Data Privacy link, and logos for the Federal Ministry of Health and the Federal Ministry of Education and Research.

Metric	Value
Funders	151
Projects	7781
Investment	6.0bn USD

Overview investments in AMR R&D

- Investments in AMR R&D
- > All sectors
- > Animal
- Environment
- > Human
- Plant
- Data Trends
- Our Data
- Antibacterials in Clinical Development
- Incentives for Antibiotic R&D

Dynamic Dashboard | INVESTMENTS IN AMR R&D

Last updated: 25.10.2020

Parameter

Number of Projects

Total Investments

Currency

USD EUR

Status

Active Closed

Reset filter

* on the years visual = incomplete years

Funders
151





Number of Projects
7781

Total Investment
USD 5.98bn

Research Organizations (RO)
1833


Countries of RO
64

One Health Sectors
2




Very limited clinical development of new antibiotics in children

- Dynamic Dashboard Pipeline representation based on data from WHO and Pew Charitable Trusts
- Information about indications from the pipeline analysis of the Access to Medicines Foundation also included
- Two recently approved products (Vabomere and Xenalta) have paediatric indications
- No search function on the pipeline representation directly - general search function finds the products with paediatric indications



Vabomere (Meropenem+Vaborbactam)	Yes	No	Small molecule	<p>DRUG NAME: Meropenem+Vaborbactam ALTERNATIVE NAME: Vabomere COUNTRY (COMPANY): USA DEVELOPMENT PHASE: Approved, FDA (8/2017), EMA (11/2018) INDICATIONS (WHO): cUTI INDICATIONS (AtM): GNB and GPB-Adaptation (additional target population: paediatric patients) / CRE-Adaptation (additional indications for infections caused by CRE)-acute pyelonephritis, cUTI, cIAI, HABP, VABP and bacteraemia ROUTE OF ADMINISTRATION: IV PATHOGENS: ACTIVE AGAINST PRIORITY PATHOGENS?: Yes INNOVATIVE?: Yes ANTI-BIOTIC CLASS: Boronate BLI + carbapenem</p>	Melinta Therapeutics (United States)
Lefamulin / Xenleta	Yes	No	Small molecule	<p>DRUG NAME: Lefamulin ALTERNATIVE NAME: Xenleta COUNTRY (COMPANY): IE DEVELOPMENT PHASE: Approved, FDA (8/2019) INDICATIONS: CAP (WHO), Community-acquired bacterial pneumonia (PEW), Multidrug-resistant GNB (including H. influenzae) and GPB (including MRSA) and atypical bacteria - Adaptation (additional target population: paediatric patients) / Multidrug-resistant GNB (including H. influenzae) and GPB (including MRSA) and atypical bac (AtM)</p>	Nabriva Therapeutics (Austria)



All AMR R&D for human sector

5,230 million USD

6837 projects

AMR R&D related to children


529 million USD
410 projects

Percentage of investment

2%
7%
11%
11%
12%
18%
38%

- Promotants
- Policy
- Other products
- Basic research
- Diagnostics
- Therapeutics
- Capacity building
- Preventives
- Operational

Number of research projects related to therapeutics for children (40 projects)



140 million USD


GARDP key player in paed. clinical stage R&D

- The GARDP studies on neonatal sepsis observational study, testing interventions (fosfomycin and possible combinations) and the paediatric investigation plan for polymyxin B represent a significant share of the overall effort
- Further clinical phase projects on PK of TB drugs, prospective study in respiratory tract infections, comparing treatments in skin and soft-tissue infections, some of the COMBACTE IMI projects address paediatric clinical work

Dynamic Dashboard gives access to early-stage information on the R&D landscape

- Dynamic Dashboard presents information about projects supported by 151 funders from across the world; expanding continuously
- Allows access to information on the R&D landscape at an early stage
- Focusing on specific questions possible through text search on (most) abstracts and filter functions
- Global AMR R&D Hub secretariat ready to support external partners for more detailed analyses

GLOBAL
AMR R&D
HUB



elmar.nimmesgern@dzif.de

<https://globalamrhub.org>

<https://dashboard.globalamrhub.org/>

<https://twitter.com/GlobalAMRHub>

Funded by:



Federal Ministry
of Health



Federal Ministry
of Education
and Research